Orgenesis Inc.

Orgenesis Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.
Looking for a particular Orgenesis Inc. employee's phone or email?

Orgenesis Inc. Questions

News

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - Yahoo Finance

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings Yahoo Finance

Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations - Frontiers

Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations Frontiers

Orgenesis loses CFO, more than half of its board - The Business Journals

Orgenesis loses CFO, more than half of its board The Business Journals

Orgenesis’s Sharp Swings Define Its High-Risk Biotech Story - Finimize

Orgenesis’s Sharp Swings Define Its High-Risk Biotech Story Finimize

Top Companies Developing Cell Therapy Treatments For Diabetes in 2025 - BioInformant

Top Companies Developing Cell Therapy Treatments For Diabetes in 2025 BioInformant

Orgenesis Acquires Control of Octomera - citybiz

Orgenesis Acquires Control of Octomera citybiz

UC Davis and Orgenesis partner to boost access to gene and cell therapies in California - University of California - Davis Health

UC Davis and Orgenesis partner to boost access to gene and cell therapies in California University of California - Davis Health

Orgenesis announces resignation of CFO and three board members - Investing.com

Orgenesis announces resignation of CFO and three board members Investing.com

Orgenesis and Johns Hopkins University to build CGT Maryland Center - BioProcess International

Orgenesis and Johns Hopkins University to build CGT Maryland Center BioProcess International

Orgenesis Completes Acquisition of Tamir Biotechnology, Inc. Assets Including Broad Spectrum Antiviral Platform - GlobeNewswire

Orgenesis Completes Acquisition of Tamir Biotechnology, Inc. Assets Including Broad Spectrum Antiviral Platform GlobeNewswire

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support - Yahoo Finance

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support Yahoo Finance

Orgenesis Inc. to be delisted from Nasdaq - Investing.com

Orgenesis Inc. to be delisted from Nasdaq Investing.com

Orgenesis signs muscle-derived stem cell pact with Revatis - BioProcess International

Orgenesis signs muscle-derived stem cell pact with Revatis BioProcess International

Orgenesis CEO Vered Caplan Provides Letter to Shareholders - GlobeNewswire

Orgenesis CEO Vered Caplan Provides Letter to Shareholders GlobeNewswire

Orgenesis subsidiary Theracell enters $1 million convertible loan agreement - Investing.com

Orgenesis subsidiary Theracell enters $1 million convertible loan agreement Investing.com

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic - Yahoo Finance

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic Yahoo Finance

Catalent to buy Orgenesis’ cell therapy CDMO biz for $315m - BioProcess International

Catalent to buy Orgenesis’ cell therapy CDMO biz for $315m BioProcess International

Orgenesis director Ashish Nanda resigns from board effective immediately - Investing.com

Orgenesis director Ashish Nanda resigns from board effective immediately Investing.com

Orgenesis announces director resignation - Investing.com

Orgenesis announces director resignation Investing.com

Orgenesis Announces Anti-Viral “BioShield” Program Designed - GlobeNewswire

Orgenesis Announces Anti-Viral “BioShield” Program Designed GlobeNewswire

Cell and Gene Therapy Manufacturing Views Mobile Options - Genetic Engineering and Biotechnology News

Cell and Gene Therapy Manufacturing Views Mobile Options Genetic Engineering and Biotechnology News

Grit Biotechnology’s TIL Therapy GT201 Cleared for US Trial in Advanced Solid Tumors - CGTLive®

Grit Biotechnology’s TIL Therapy GT201 Cleared for US Trial in Advanced Solid Tumors CGTLive®

Orgenesis agrees to take over Koligo Therapeutics - Pharmaceutical Technology

Orgenesis agrees to take over Koligo Therapeutics Pharmaceutical Technology

Orgenesis secures $2.3 million investment and strategic partnership By Investing.com - Investing.com

Orgenesis secures $2.3 million investment and strategic partnership By Investing.com Investing.com

Orgenesis Signs Master Service and Joint Venture Agreement - GlobeNewswire

Orgenesis Signs Master Service and Joint Venture Agreement GlobeNewswire

Market Recap: Why Orgenesis Inc. (45O) stock gets analyst attention - Weekly Trade Analysis & Risk Managed Investment Signals - Trung tâm Dự báo KTTV quốc gia

Market Recap: Why Orgenesis Inc. (45O) stock gets analyst attention - Weekly Trade Analysis & Risk Managed Investment Signals Trung tâm Dự báo KTTV quốc gia

Orgenesis inks Koligo buyout to gain COVID-19 cell therapy - Fierce Biotech

Orgenesis inks Koligo buyout to gain COVID-19 cell therapy Fierce Biotech

Orgenesis, SCTbio Partner to Expand POCare Sites in Czech Republic - Contract Pharma

Orgenesis, SCTbio Partner to Expand POCare Sites in Czech Republic Contract Pharma

Vered Caplan - The Medicine Maker

Vered Caplan The Medicine Maker

Treating diabetes with autologous cell therapy: an interview with Orgenesis - RegMedNet

Treating diabetes with autologous cell therapy: an interview with Orgenesis RegMedNet

Orgenesis, Cure Therapeutics to advance point-of-care development and commercialization of cell and gene therapies - SelectScience

Orgenesis, Cure Therapeutics to advance point-of-care development and commercialization of cell and gene therapies SelectScience

Orgenesis acquires cell therapy specialist Koligo for $15m - BioProcess International

Orgenesis acquires cell therapy specialist Koligo for $15m BioProcess International

Orgenesis (ORGS) Stock Price, News & Analysis - MarketBeat

Orgenesis (ORGS) Stock Price, News & Analysis MarketBeat

Orgenesis Announces Publication of an Independent Study - GlobeNewswire

Orgenesis Announces Publication of an Independent Study GlobeNewswire

Orgenesis Tackles Cell Therapy Costs, Barriers With Decentralized Model - Precision Medicine Online

Orgenesis Tackles Cell Therapy Costs, Barriers With Decentralized Model Precision Medicine Online

Precision Medicines That Are Tailored and Off-the-Rack - Genetic Engineering and Biotechnology News

Precision Medicines That Are Tailored and Off-the-Rack Genetic Engineering and Biotechnology News

Orgenesis and Johns Hopkins University to create Maryland center for cell therapy manufacturing - Proactive financial news

Orgenesis and Johns Hopkins University to create Maryland center for cell therapy manufacturing Proactive financial news

Orgenesis Signs Master Service and JV Agreement - Contract Pharma

Orgenesis Signs Master Service and JV Agreement Contract Pharma

Ezra Merkin, Hedge Fund Manager Scarred by Madoff Scandal, Buys into Orgenesis - citybiz

Ezra Merkin, Hedge Fund Manager Scarred by Madoff Scandal, Buys into Orgenesis citybiz

StockNewsNow.com Publishes New SNNLive Video Interview With Orgenesis - BioSpace

StockNewsNow.com Publishes New SNNLive Video Interview With Orgenesis BioSpace

Germfree partners with Orgenesis to enhance CGT production By Investing.com - Investing.com UK

Germfree partners with Orgenesis to enhance CGT production By Investing.com Investing.com UK

Orgenesis Inc Stock Price Today | OTC: ORGS Live - Investing.com

Orgenesis Inc Stock Price Today | OTC: ORGS Live Investing.com

Debunked: Ursula von der Leyen's husband is not the director of a company owned by Pfizer - The Journal

Debunked: Ursula von der Leyen's husband is not the director of a company owned by Pfizer The Journal

Pfizer Does Not Own Orgenesis: So Why Does This Misinformation Trend on X? - pandata.org

Pfizer Does Not Own Orgenesis: So Why Does This Misinformation Trend on X? pandata.org

Top Orgenesis Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant